Berkshire Hathaway: There Is Still Value Even Without Buffett

Berkshire Hathaway is estimated to have intrinsic value of $520 per share, about 10% above the current market price, with the insurance business valued at $278 per share. The article highlights continued resilience from Berkshire’s float and statutory capital, plus potential for more aggressive share repurchases. It also points to disciplined deployment of roughly $35B in annual investable cash flow as capital allocation shifts post-Buffett.

Analysis

BRK.B is functioning less like a single stock and more like a self-funding balance sheet with an embedded call option on market dislocations. The key second-order effect is that as the public-market opportunity set stays more expensive, Berkshire’s relative advantage increases: it can harvest insurance float, buy back equity, and sit on cash without needing growth to justify the capital base. That makes the post-Buffett transition less about headline leadership risk and more about whether capital allocation remains disciplined enough to preserve the compounding machine.

The biggest beneficiaries are likely Berkshire’s own equity holders and, paradoxically, the sellers of high-quality assets in stressed periods who need a patient bid. Competitively, private equity and strategic buyers lose some flexibility because Berkshire can underwrite deals with a lower hurdle rate and less leverage, which matters if credit tightens or refinance windows close. Insurance peers are less directly advantaged; Berkshire’s scale in float and statutory capital is a structural moat that is hard to replicate and may become more valuable if catastrophe losses or reserve pressure make underwriting discipline scarcer across the sector.

The risk is not operational collapse but capital allocation drift: a more aggressive buyback regime could be additive if executed below intrinsic value, but destructive if management starts defending optics rather than economics. The time horizon is months to years, not days; the near-term catalyst is whether repurchases accelerate on any broad-market weakness, while the tail risk is that the market assigns a governance discount to the post-Buffett era before proving continuity. A reversal would likely require either a major change in buyback discipline, a deterioration in underwriting tail performance, or a broad equity drawdown that makes Berkshire’s cash hoard look less like optionality and more like underdeployment.

Consensus may be underestimating how much Berkshire benefits from a higher-rate, lower-liquidity regime: cash and float become more valuable when financing is expensive and volatility creates forced sellers. The stock may also be over-discounting succession risk relative to the durability of the operating model; the transition risk is real, but the moat is institutional, not personality-based. That suggests the market is pricing a modest governance haircut while leaving less room for a re-rating if Berkshire proves it can keep compounding through buybacks and opportunistic deployment.

Key Decisions for Investors

• Add BRK.B on pullbacks over the next 1-3 months; treat any 3-5% market-driven weakness as an entry point for a 6-12 month hold. Risk/reward favors upside from buyback acceleration and capital deployment optionality, with downside cushioned by balance sheet strength.
• Buy BRK.B Jan-2026 calls or call spreads on any post-earnings volatility compression. The setup is asymmetric if the market continues to reward cash-rich balance sheets and the transition proves operationally seamless.
• Pair long BRK.B / short KKR or BX for 6-9 months as a higher-rate regime trade. Berkshire benefits from patient capital and internal funding flexibility, while leveraged capital allocators face a tougher exit and fundraising backdrop.
• If BRK.B rallies toward a premium to the implied intrinsic value range, trim 20-30% and wait for a better entry. The stock is attractive, but multiple expansion should be capped unless repurchases clearly outpace cash accumulation.